Clinical trials: Moderate-to-severe Psoriasis
Effects, Drug Side
An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis in order to select doses for further clinical trials.
- Trial name
- NCT05858047
- Testing
- SYHX1901
- Where
- China
- Volunteers
- 93 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Brief Description of Focus of Study
A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis
Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06912165
- Testing
- WD-890 tablet
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Wenda Pharma Technology LTD.
Plaque Type Psoriasis
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira
The aim of the study is to demonstrate equivalent efficacy and similarity in the safety profile of GP2017 and Humira® in patients with moderate to severe chronic plaque-type psoriasis.
- Trial name
- ADACCESS (NCT02016105)
- Testing
- GP2017 Adalimumab, Humira ® Adalimumab
- Where
- 79 sites in United States, Bulgaria and 2 more
- Volunteers
- 465 people
- Sponsor
- Sandoz
Psoriasis
Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in subjects with moderate to severe psoriasis to assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and…
- Trial name
- NCT02156466
- Testing
- MSB0010841
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Moderate to Severe Psoriasis
CLEAR Study: Clinical Experience Acquired With Raptiva Study
A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered Raptiva in the treatment of patients with moderate to severe psoriasis
- Trial name
- NCT00256139
- Testing
- Raptiva
- Where
- Switzerland
- Volunteers
- 793 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Plaque Psoriasis
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
- Trial name
- CLARITY (NCT02826603)
- Testing
- Secukinumab, Ustekinumab
- Where
- 154 sites in United States, Canada and 9 more
- Volunteers
- 1,114 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis
The purpose of this study is to achieve a better understanding of clinical characteristics, treatment patterns and clinical outcomes of participants with moderate-to-severe plaque psoriasis (PsO) as well as their unmet medical…
- Trial name
- NCT05547490
- Where
- 2 sites in China
- Volunteers
- 3,506 people
- Sponsor
- Bristol-Myers Squibb
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Moderate to Severe
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.
- Trial name
- NCT00162253
- Testing
- BMS 587101
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03556202
- Testing
- Mirikizumab
- Where
- 229 sites in United States, Argentina and 17 more
- Volunteers
- 1,936 people
- Sponsor
- Eli Lilly and Company
Psoriasis, Psoriasis Palmaris
Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines
French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults have been developed by the psoriasis research group of the French Society of Dermatology using literature available until July 2017…
- Conditions
- Psoriasis, Psoriasis Palmaris, Psoriasis Inverse, Psoriasis Vulgaris
- Trial name
- NCT05144165
- Testing
- Experts consensus
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre of Evidence of the French Society of Dermatology
Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
The purpose of this study was to evaluate the safety and effectiveness of an investigational drug called doxercalciferol in participants with moderate to severe chronic plaque psoriasis, in comparison with a placebo ("sugar…
- Trial name
- NCT00601107
- Testing
- Doxercalciferol
- Where
- 19 sites in United States
- Volunteers
- 111 people
- Sponsor
- Genzyme, a Sanofi Company
Moderate to Severe Plaque Psoriasis
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT05342428
- Testing
- TLL018 tablets
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Psoriatic Arthritis
Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis
Psoriatic arthritis is a heterogeneous chronic inflammatory disorder involving joints, tendon sheaths, entheses, and the axial skeleton as well as skin and nails. This is an open-label trial with H.P.
- Trial name
- NCT01939132
- Testing
- Open label H.P. Acthar Gel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fiechtner, Justus J., M.D., P.C.
Psoriasis
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- CHAMPION (NCT00235820)
- Testing
- adalimumab, MTX
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Abbott
Psoriasis
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who receive ustekinumab following an inadequate response to methotrexate therapy.
- Trial name
- TRANSIT (NCT01059773)
- Testing
- Ustekinumab, Methotrexate
- Where
- 76 sites in Austria, Belgium and 17 more
- Volunteers
- 490 people
- Sponsor
- Janssen-Cilag International NV
Psoriasis Vulgaris
A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.
- Trial name
- NCT02106195
- Testing
- Belumosudil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Kadmon Corporation, LLC
Plaque Psoriasis
Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis
The purpose of the study is to assess the safety and efficacy of an injectable biologic and U0279 as combination therapy compared to that of an injectable biologic alone for severe plaque-type psoriasis.
- Trial name
- NCT00832364
- Testing
- Acitretin (also called U0279), Etanercept
- Where
- 3 sites in United States
- Sponsor
- Stiefel, a GSK Company
Genital Psoriasis, Psoriasis
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.
- Trial name
- IXORA-Q (NCT02718898)
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company
Moderate to Severe Plaque Psoriasis
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of…
- Trial name
- NCT07051538
- Testing
- SHR-1139 Injections
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd